Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q3 Report 2019

November 7, 2019

Q2 Report 2019

August 7, 2019

Q1 Report 2019

May 9, 2019

Investor presentations

JP Morgan Healthcare Conference, San Francisco, 15th January 2020

Linzagolix Phase 3 PRIMROSE 2 Trial Results

Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019

Investor Presentation November 2019

Cantor Global Healthcare Conference October 4 2019

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

Wedbush Presentation August 2019 in NYC

KOL Event in NYC July 2019

1 2

Press Releases

ObsEva SA announces CHF 32 Million Series A funding from leading Venture Capital firms and a license agreement with MerckSerono

press release

August 29, 2013

Geneva, Switzerland, 29 August 2013 – ObsEva today announced the closing of a CHF 32 million Series-A financing round (€25.6 million)….

Read more

Other ObsEva press releases

press release

January 1, 2000

Read more
1 42 43 44

General Meetings

ObsEva Annual General Meeting 2019

May 8, 2019

Read more

ObsEva Annual General Meeting 2018

May 9, 2018

Read more
1 2

Upcoming Events

Year End 2020 Financial Results week of 01 March 2021

Event

March 1, 2021


Read more

Half Year 2020 Financial Results week of 03 August 2020

Event

August 3, 2020


Read more

ObsEva Annual General Meeting 2020: Thursday May 7, 2020

Event

May 7, 2020


Read more
1 2
 

Contacts

ObsEva Switzerland Office

+41 (0)22 552 3840


contact@obseva.ch

ObsEva U.S. Office

+1 857 972 9364


contact@obseva.ch

Media Switzerland & Europe

Mario Corso

Senior Director, Investor Relations

+1 857 972 9347 Office

+1 781 366 5726 Mobile

mario.corso@obseva.com

Media United States

Mario Corso

Senior Director, Investor Relations

+1 857 972 9347 Office

+1 781 366 5726 Mobile

mario.corso@obseva.com

Investor relations




ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.

 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue